TP53 and breast cancer: However, for many users, standard GUIs lack accessibility and can require minutes to answer questions such as, “What percentage of TCGA breast cancer patients have TP53 mutations?” Modern interfaces – particularly those leveraging augmented intelligence – show promise to streamline inquiries, democratize analytics, and enhance digital health applications in cancer genomics3,4.